Watch KRYS. Know when insiders buy.
One email the day a filing lands. Free.
Work order
38
FLAG · insiders 25, shorts 50
Insiders, 90 days
−$18M
net selling · 0 buys, 26 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
2 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $10.6BP/E 44.9DIV YIELD —FCF YIELD 2.43%REV TTM $440.5M +22.6%NET INCOME $241.5M +64.6%NET CASH $423.5M52W 137.46 – 378.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $119.2M | +24.1% | — | $58.4M | $54.8M | +42.9% | 1.79 | $74.8M | $3.6M | $71.2M | Aug 3 |
| Q1 2026 · Mar 31 | $116.4M | +31.9% | — | $53.7M | $55.9M | +56.5% | 1.83 | $80.4M | $7.1M | $73.2M | Aug 3 |
| Q4 2025 · Dec 31derived | $107.1M | +17.5% | — | $44.3M | $51.4M | +13.0% | 1.70 | $77.5M | $2.1M | $75.4M | Feb 17 |
| Q3 2025 · Sep 30 | $97.8M | +16.6% | — | $41.4M | $79.4M | +192.0% | 2.66 | $39.7M | $1.7M | $38M | Nov 3 |
| Q2 2025 · Jun 30 | $96M | +36.6% | — | $39.4M | $38.3M | +146.2% | 1.29 | $52.7M | $1.9M | $50.8M | Aug 3 |
| Q1 2025 · Mar 31 | $88.2M | +94.9% | — | $36.3M | $35.7M | +3734.0% | 1.20 | $31M | $6.2M | $24.8M | Aug 3 |
| Q4 2024 · Dec 31derived | $91.1M | +116.3% | — | $41.4M | $45.5M | +423.2% | 1.53 | $52.8M | $801K | $52M | Feb 17 |
| Q3 2024 · Sep 30 | $83.8M | +879.9% | — | $22.5M | $27.2M | −66.3% | 0.91 | $58.9M | $1M | $57.8M | Nov 3 |
| Q2 2024 · Jun 30 | $70.3M | — | — | $8.6M | $15.6M | — | 0.53 | −$4.2M | $1.1M | −$5.3M | Nov 3 |
| Q1 2024 · Mar 31 | $45.3M | — | — | −$6.7M | $932K | — | 0.03 | $15.9M | $1.3M | $14.6M | Nov 3 |
| Q4 2023 · Dec 31derived | $42.1M | — | — | $3.2M | $8.7M | — | 0.31 | −$7.2M | $1.8M | −$9.1M | Feb 17 |
| Q3 2023 · Sep 30 | $8.6M | — | — | −$26M | $80.7M | — | 2.79 | −$21.2M | $1.8M | −$23M | Nov 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $389.1M | — | $161.3M | $204.8M | 52.6% | 6.84 | $200.9M | $12M | $188.9M | — | — |
| FY2024 · to Dec 31 | $290.5M | — | $65.7M | $89.2M | 30.7% | 3.00 | $123.4M | $4.2M | $119.2M | — | — |
| FY2023 · to Dec 31 | $50.7M | — | −$109.6M | $10.9M | 21.6% | 0.39 | −$88.8M | $11.8M | −$100.6M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$145.2M | −$140M | — | -5.49 | −$100.6M | $53M | −$153.5M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$68.3M | −$69.6M | — | -3.13 | −$47.9M | $68.3M | −$116.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$33M | −$32.2M | — | -1.71 | −$26.1M | $14.8M | −$40.9M | — | — |
Every number comes from Krystal Biotech, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.